Latest results FY2026 · Prices updated Oct 30, 2026
HQ: Osaka, OsakaFounded 18901,884 employeesWebsite
A pharmaceutical company focused on ophthalmology, with a broad portfolio of eye-care products in Japan and overseas. It leverages specialized expertise and research capabilities to advance eye health.
Business segments (share of revenue)
Latest results
FY2026
vs. same period a year earlier
Company forecastFY2027
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| Single Operating Segment | 100% | ¥291.6B | ¥47.8B | 16.4% |
Close (Oct 30, 2026)
¥1,789.5+21.9% (1Y)
Santen +21.9% over 1Y, 9.8pt above the industry average (23 companies, +12.2%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2026FY | ¥291.6B | ¥47.8B | ¥37.4B | ¥423.0B | — |
Sources: annual securities reports, earnings releases and other public disclosures (Jan 2026)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
